Evidence map›Paper›PMID 36698298›Full record

ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2023

Plasmon-Enhanced Single Extracellular Vesicle Analysis for Cholangiocarcinoma Diagnosis.

Mi Ho Jeong, Taehwang Son, Yoo Keung Tae, Chan Hee Park, Hee Seung Lee, Moon Jae Chung, Jeong Youp Park, Cesar M Castro, Ralph Weissleder, Jung Hyun Jo and 2 more

Open access · goldFull text read
In one paragraph

Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed
7.2field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

26 citing papers in PubMed, 47 citations in OpenAlex.

  1. Article
  2. Article
  3. Do drugs with biliary toxicity cause cholangiocarcinoma?bioRxiv : the preprint server for biology · 2026
    Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Review
  9. Article
  10. Review
  11. Article
  12. Review
  13. Review
  14. Review
  15. Review
  16. Review
  17. Extracellular vesicles: key mediators inFrontiers in veterinary science · 2025
    Review
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 2 countries.

Mi Ho JeongCenter for Systems Biology, Massachusetts General Hospital, Boston, MA, 02114, USA.
Taehwang SonCenter for Systems Biology, Massachusetts General Hospital, Boston, MA, 02114, USA.
Yoo Keung TaeDivision of Gastroenterology, Department of Internal Medicine, Severance Hospital, Yonsei University College of Medicine, Seoul, 03722, Republic of Korea.
Chan Hee ParkDivision of Gastroenterology, Department of Internal Medicine, Severance Hospital, Yonsei University College of Medicine, Seoul, 03722, Republic of Korea.
Hee Seung LeeDivision of Gastroenterology, Department of Internal Medicine, Severance Hospital, Yonsei University College of Medicine, Seoul, 03722, Republic of Korea.
Moon Jae ChungDivision of Gastroenterology, Department of Internal Medicine, Severance Hospital, Yonsei University College of Medicine, Seoul, 03722, Republic of Korea.
Jeong Youp ParkDivision of Gastroenterology, Department of Internal Medicine, Severance Hospital, Yonsei University College of Medicine, Seoul, 03722, Republic of Korea.
Cesar M CastroCenter for Systems Biology, Massachusetts General Hospital, Boston, MA, 02114, USA.
Ralph WeisslederCenter for Systems Biology, Massachusetts General Hospital, Boston, MA, 02114, USA.
Jung Hyun JoDivision of Gastroenterology, Department of Internal Medicine, Severance Hospital, Yonsei University College of Medicine, Seoul, 03722, Republic of Korea.
Seungmin BangDivision of Gastroenterology, Department of Internal Medicine, Severance Hospital, Yonsei University College of Medicine, Seoul, 03722, Republic of Korea.
Hyungsoon ImCenter for Systems Biology, Massachusetts General Hospital, Boston, MA, 02114, USA.ORCID 0000-0002-0626-1346
Yonsei University · KRMassachusetts General Hospital · USHarvard University · US

Funding

Development of plasmon-enhanced biosensing for multiplexed profiling of extracellular vesiclesR01GM138778 · NIGMS · MASSACHUSETTS GENERAL HOSPITAL · PI IM, HYUNGSOON · 2020 to 2024
$2.3M
Nano-plasmonic technology for high-throughput single exosome analysesR21CA217662 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI IM, HYUNGSOON · 2019 to 2021
$585k
Ministry of Trade, Industry, and Energy, Republic of Korea 20008829National Research Foundation of Korea NRF-2021R1A6A3A14039686NCI NIH HHS R21 CA217662NCI NIH HHS R21CA217662NIGMS NIH HHS R01 GM138778NIGMS NIH HHS R01GM138778Severance Hospital Research Fund for Clinical Excellence C-2018-0008Severance Hospital Research Fund for Clinical Excellence C-2019-0036
6 · The paper itself

Abstract

Cholangiocarcinoma (CCA) is a fatal disease often detected late in unresectable stages. Currently, there are no effective diagnostic methods or biomarkers to detect CCA early with high confidence. Analysis of tumor-derived extracellular vesicles (tEVs) harvested from liquid biopsies can provide a new opportunity to achieve this goal. Here, an advanced nanoplasmonic sensing technology is reported, termed FLEX (fluorescence-amplified extracellular vesicle sensing technology), for sensitive and robust single EV analysis. In the FLEX assay, EVs are captured on a plasmonic gold nanowell surface and immunolabeled for cancer-associated biomarkers to identify tEVs. The underlying plasmonic gold nanowell structures then amplify EVs' fluorescence signals, an effective amplification process at the single EV level. The FLEX EV analysis revealed a wide heterogeneity of tEVs and their marker levels. FLEX also detected small tEVs not detected by conventional EV fluorescence imaging due to weak signals. Tumor markers (MUC1, EGFR, and EPCAM) are identified in CCA, and this marker combination is applied to detect tEVs in clinical bile samples. The FLEX assay detected CCA with an area under the curve of 0.93, significantly better than current clinical markers. The sensitive and accurate nanoplasmonic EV sensing technology can aid in early CCA diagnosis.

Indexed as

Bile Duct NeoplasmsCholangiocarcinomaExtracellular VesiclesBile Ducts, IntrahepaticBiomarkers, TumorHumansBiomarkers, Tumorbiomarkerscholangiocarcinomadiagnosticsextracellular vesiclesplasmonics

Identifiers

PMID36698298
PMCPMC10015870
OpenAlexW4318168542

What OpenQuestion holds

Textfull text, public
LicenceCC BY
measurements read75
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.